TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00771459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5 %
Description: Local infiltration analgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Local infiltration analgesia
Study: NCT01125904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
Study: NCT02142712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
Study: NCT02012075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Carvedilol Sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Metoprolol Succinate
Study: NCT04956367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma
Description: Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma
Description: Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser with PRP
Description: CO2 laser with PRP

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CO2 laser with placebo
Description: CO2 laser with placebo
Study: NCT03971058

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IXIARO®- Japanese Encephalitis vaccine
Description: Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
Study: NCT02339454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active treatment group
Description: Energy Density - 0.09 mJ/mm2 Device: Active Applicator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo Applicator
Study: NCT01001624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melanil facial cream
Description: Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone 2% cream
Description: Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
Study: NCT03570671

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spasm positive
Description: Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Spasm negative
Description: Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
Study: NCT01664130

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00881686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine
Description: 1.5mg/Kg adenosine will be administered intravenously before surgery
Study: NCT02819583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCAR-019 (anti-CD19 CAR-T cells)
Study: NCT00567905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: main content is epigallocatechin gallate (EGCG, 58%)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green tea extract
Description: main content is epigallocatechin gallate (EGCG, 58%)
Study: NCT00660400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacitidine
Description: Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Cell Transplantation (HCT)
Description: Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant.
Study: NCT03515590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsion with solid droplets
Description: This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsion with liquid droplets
Description: This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
Study: NCT03565679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDLINE RENEWAL PULSE OXIMETRY SENSORS
Description: An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO-OXIMETRY SENSORS
Description: A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
Study: NCT02258854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 gevokizumab
Description: Solution for subcutaneous injection
Study: NCT03116971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
Study: NCT04835051

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding promotion
Description: The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
Study: NCT02094612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quotient®
Description: Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinic ADHD Care
Description: Usual ADHD care as provided by the clinic
Study: NCT04258761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: Active test article

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: Active test article

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: Active test article

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: Active test article

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: Active test article
Study: NCT03248960

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iTreat Flu A+B Test
Description: The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ellume.lab Flu A+B Test
Description: The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Description: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Viral culture
Description: Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
Study: NCT03298048

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fecal microbiota dose
Description: receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mid fecal microbiota dose
Description: receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High fecal microbiota dose
Description: receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
Study: NCT04096404

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotype- based personalised advice
Description: Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non genetic personalised advice
Description: Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non genetic personalised advice
Description: Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
Study: NCT02698852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme
Description: Stent platform: cobalt-chromium alloy
Study: NCT03116971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
Study: NCT02056340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00119054

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In Home Health Messaging Device
Study: NCT01190774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information to health provider without patient knowledge
Description: The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dentist behaviour and patient expectancy
Description: patient give information about their dental anxiety to the dentist
Study: NCT01655472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging follow up: MRI scan
Description: .1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging follow up: MRI scan
Description: .1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging follow up: Ultrasonographic examination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging follow up: Ultrasonographic examination
Study: NCT03781596

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Retrospective evaluation of endoscopy prior to study drug
Description: Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Retrospective evaluation of endoscopy prior to study drug
Description: Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: Patient will complete symptom survey prior to starting the study drugs.
Study: NCT02966665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine, Ranitidine
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine, Ranitidine
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
Study: NCT01173822

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Ultrafiltration of residual blood
Description: The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrafiltration of residual blood
Description: The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
Study: NCT00479128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
Study: NCT00846027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was supplied as a sterile liquid in glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was supplied as a sterile liquid in glass vials.
Study: NCT00058318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
Study: NCT02660060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Dexa Medica
Description: Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Boehringer Ingelheim Pharma
Description: Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
Study: NCT03345849

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet